Trial · NCT03444870
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 11 of 11
Download this page as JSON| Comparison | Source |
|---|---|
| Global - OLE Period: Gantenerumab (DBT) to Gantenerumab vs Global - OLE Period: Placebo (DBT) to Gantenerumab: OLE Period: Number of Participants With at Least One ARIA-H MRI Finding | Trial comparisons |
| China Extension - DBT Period: Gantenerumab vs China Extension - DBT Period: Placebo: China - DBT Period: Number of Participants With Injection-Site Reactions | Trial comparisons |
| Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With Injection-Site Reactions | Trial comparisons |
| Global - OLE Period: Gantenerumab (DBT) to Gantenerumab vs Global - OLE Period: Placebo (DBT) to Gantenerumab: OLE Period: Number of Participants With at Least One AEs | Trial comparisons |
| China Extension - DBT Period: Gantenerumab vs China Extension - DBT Period: Placebo: China - DBT Period: Number of Participants With at Least One AE | Trial comparisons |
| Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Adverse Event (AE) | Trial comparisons |
Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding | Trial comparisons |
| Global - OLE Period: Gantenerumab (DBT) to Gantenerumab vs Global - OLE Period: Placebo (DBT) to Gantenerumab: OLE Period: Number of Participants With at Least One ARIA-E MRI Finding | Trial comparisons |
| China Extension - DBT Period: Gantenerumab vs China Extension - DBT Period: Placebo: China - DBT Period: Number of Participants With at Least One ARIA-H MRI Finding | Trial comparisons |
Global - DBT Period: Gantenerumab vs Global - DBT Period: Placebo: DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding | Trial comparisons |
| China Extension - DBT Period: Gantenerumab vs China Extension - DBT Period: Placebo: China - DBT Period: Number of Participants With at Least One ARIA-E MRI Finding | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03444870/comparisons